{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-102027","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2025-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.609988+00:00","generated_at":"2026-05-17T21:29:48.336659+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CRISPR Therapeutics Q2 net loss $208.5M; CASGEVY hits 75 ATCs, 115 cell collections; CTX310 shows 86% LDL reduction","bullets":["Net loss of $208.5M in Q2 2025 vs $126.4M in Q2 2024; cash & securities $1.72B down from $1.90B at end-2024.","CASGEVY momentum: >75 authorized treatment centers activated, ~115 patients had cells collected, 29 received infusions (16 in Q2).","CTX310 Phase 1 data: dose-dependent TG reduction up to 82% and LDL reduction up to 86% after single administration; full data H2 2025.","EMA authorized Phase 2 trial for SRSD107 (Factor XI siRNA) in thromboembolic disorders; $25M upfront to partner Sirius Therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-102027","json":"https://secwatch.observer/filing/0000950170-25-102027.json","markdown":"https://secwatch.observer/filing/0000950170-25-102027.md","text":"https://secwatch.observer/filing/0000950170-25-102027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000095017025102027/0000950170-25-102027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000095017025102027/crsp-20250804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:29:48.336659+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}